Added to YB: 2025-09-29
Pitch date: 2025-06-30
NEO [neutral]
NeoGenomics, Inc.
+63.22%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
Market Cap
$1.0B
Pitch Price
$7.26
Price Target
N/A
Dividend
N/A
EV/EBITDA
332.12
P/E
-9.59
EV/Sales
1.84
Sector
Health Care Providers and Services
Category
growth
Show full summary:
Alger Weatherbie Specialized Growth Fund Portfolio Holding: NeoGenomics, Inc.
NEO (holding update): Leading oncology lab testing provider w/ competitive moats in comprehensive testing menu & nationwide footprint. Q4 revenue slightly below est due to pharma services weakness from reduced biopharma funding, but beat EBITDA consensus. 2025 organic revenue guidance reaffirmed.
Read full article (1 min)